ABEO Stock Analysis: Buy, Sell, or Hold?
ABEO - Abeona Therapeutics Inc. Common Stock
$5.67
-0.02 (-0.35%)
▼
5d:
-0.35%
30d:
-4.71%
90d:
+14.08%
BUY
HIGH Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When ABEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ABEO this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ABEO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: ABEO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.64
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.36
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABEO is currently trading at $5.67, which is considered fair relative to its 30-day fair value range of $5.38 to $5.82. The stock's valuation (Forward PE: 19.9) is in line with its historical norms (21.5). Remarkably, the market is currently pricing in an annual earnings decline of 2.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ABEO is in a uptrend. Immediate support is located at $5.08, while resistance sits at $5.93.
Market Sentiment: ABEO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.71 (+246.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABEO is in a uptrend. Immediate support is located at $5.08, while resistance sits at $5.93.
Market Sentiment: ABEO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $19.71 (+246.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$5.38 -
$5.82
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 246.5% below Wall St target ($19.71)
Trading Range Analysis
30-Day Trading Range
$5.38 -
$5.82
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.70
(12.3%)
Support & Resistance Levels
Support Level
$5.08
Resistance Level
$5.93
Current Trend
Uptrend
Technical data as of
Jun 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.85
Wall Street Target
$19.71
(+246.5%)
Revenue Growth (YoY)
-100.0%
Profit Margin
454.9%
Valuation Discount vs History
-2.6% cheaper
PE vs Historical
19.9 vs 21.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.6%
(market-implied from PE analysis)
1-Year Target
$5.54
(-3%)
2-Year Target
$5.40
(-5%)
3-Year Target
$5.26
(-8%)
3-Yr Target (if PE normalizes)
(PE: 20→22)
$5.70
(+0%)
📈
Valuation based on Current Earnings
Trailing PE: 5.97 | Current EPS (TTM): $0.95
Bull Case
$3.12
(-46%)
Analyst growth -50.0%, PE expands to 6.6
Base Case
$2.84
(-51%)
Market implied -50.0%, PE stable at 6.0
Bear Case
$3.86
(-33%)
Severe decline -20.0%, PE contracts to 5.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 19.8 to 21.5
Stabilization Target:
$6.16
(+8.3%)
PE Expansion Potential:
+8.3%
Share & Embed Analysis
Last updated: June 03, 2026 4:48 PM ET
Data refreshes hourly during market hours. Next update: 5:48 PM
Data refreshes hourly during market hours. Next update: 5:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Crombez
SELL
16284 shares
2026-02-02
Leila Alland
SELL
18065 shares
2026-02-02
Mark Alvino
SELL
2000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1023 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$82 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 54 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 48 HOLD |
